Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Filings indexed 767 across all filing types
Latest filing 2022-08-11 Earnings Release
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Second Quarter and Half-Year Results
Earnings Release Classification · 100% confidence The document is a press release titled 'MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results'. It contains key financial highlights, revenue guidance, and a summary of operating results for the specified period. It is not a full 10-Q or 10-K report, but rather the initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q2 2022
2022-08-11 English
Filing of Form 10-Q for Second Quarter
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. stating that they have filed their Form 10-Q for the quarterly period ended June 30, 2022. It provides links to where the report can be found but does not contain the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2022-08-11 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-10 English
8-K
Regulatory Filings
2022-08-10 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is an RNS announcement from MaxCyte, Inc. regarding the issuance of new common stock following the exercise of share options and the subsequent update to the total voting rights (denominator for shareholder notifications). This falls under the category of share capital changes and issuance.
2022-08-02 English
Notice of Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. stating that they will release their second quarter 2022 financial results on a future date (August 10, 2022) and providing details for an upcoming conference call. Per the 'Menu vs Meal' rule, this is an announcement regarding the timing of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2022-07-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.